ArticlePflugers Archiv : European journal of physiology2026
Upregulation of T-type voltage-dependent Ca²⁺ channels in activated hepatic stellate cells promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis.
Article in Pflugers Archiv : European journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- STIM/Orai-Mediated Store-Operated CaCells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of hepatic stellate cells (HSCs) is a pivotal event in the development of liver fibrosis, a pathological process that precedes cirrhosis and hepatocellular carcinoma and for which effective therapies remain limited. The molecular mechanisms underlying HSC activation, particularly the ion channels that regulate cytosolic Ca²⁺ signaling that promote fibrogenesis, remain incompletely understood. In this study, the expression and functional roles of Ca²⁺ channels in human and mouse HSCs were investigated using quantitative real-time PCR, Western blotting, whole-cell patch-clamp electrophysiology, Ca2+ imaging, and histological analyses. RNA sequencing of human HSCs revealed upregulation of CaV3.2 transcripts upon activation. In activated human HSCs (LX-2 cells), CaV3.2 protein was detected, and transient inward currents sensitive to the T-type voltage-dependent Ca²⁺ channel (T-VDCC) blocker Z944 were recorded. Z944 concentration-dependently reduced both resting cytosolic Ca2+ concentration ([Ca2+]cyt) and mRNA levels of activation markers (ACTA2 and COL3A1) in LX-2 cells. In mouse HSCs, CaV3.1 and CaV3.2 mRNA and protein expression increased during activation and were accompanied by Z944-sensitive inward currents. Among T-VDCC isoforms, CaV3.2 was identified as the predominant contributor to both T-type Ca²⁺ currents and resting [Ca2+]cyt. In a mouse model of metabolic dysfunction-associated steatohepatitis (MASH), CaV3.2 expression was selectively elevated in HSCs. Notably, administration of Z944 significantly attenuated MASH-associated liver fibrosis compared with controls. Collectively, these findings demonstrate that CaV3.2 expression and activity are upregulated during HSC activation, resulting in enhanced cytosolic Ca²⁺ signaling and fibrogenic responses. CaV3.2 may therefore represent a potential therapeutic target for liver fibrosis.
Indexed as
Identifiers
41915213What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.